In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
A devastating invasive pest with no known natural predators threatens recreational areas, forests, and suburban and urban shade trees. Once a tree is infested, it must be removed, which is why the United States Department of Agriculture (USDA) has designated August as Tree Check Month to encourage the public to look for signs of a devastating invasive pest, the Asian longhorned beetle (ALB). The USDA is asking for help spreading the word about how the public can help save trees with a PSA TV spot, radio scripts, and print advertisements.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7277051-usda-august-tree-check-month-asian-longhorned-beetle-invasive-pest-psa/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
The Alfred Mann Foundation (AMF) today announced the first subject, a U.S. Marine, SSgt James Sides, as a recipient of its highly anticipated IMES System (implantable myoelectric sensor) – an experimental system that holds the promise of being the first minimally invasive, intuitive, multi-channel control system for prosthetics intended for long term use. The IMES System is currently being studied under the Investigational Device Exemption (IDE) regulations of the U.S. Food and Drug Administration (FDA). AMF’s ongoing trial with injured veterans at the Walter Reed National Medical Military Center anticipates subjects intuitively operating three different prosthetic movements simultaneously: opening and closing the hand, rotating the wrist, and moving the thumb. Combining these three movements enables several grasps that are invaluable for performing everyday tasks.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65112-alfred-mann-foundation-u-s-marine-subject-fda-study-for-imes-system
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
Bone and Joint Center is a center of hip excellence for arthroscopic surgery of sports-related injuries, FAI, hip impingement, ACL, labral tears and also minimally invasive anterior approach total hip replacement.
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Today, Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic treatments, announced the arrival of its groundbreaking Liposonix technology in the United States and Canada. Using advanced high-intensity focused ultrasound (HIFU) technology, Liposonix is a non-surgical permanent fat reduction procedure that has been clinically shown to slim down the waistline by one pant or dress size without surgery or downtime. It is indicated for non-invasive waist circumference reduction for use on both the abdomen and love handles.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54037-solta-liposonix-custom-contouring-waistline-fat-reduction
Prem Rabindranauth, MD, a heart surgeon at Gundersen Lutheran Health System in La Crosse, Wis., is using an exciting technique, called minimally invasive coronary surgery (MICS), to perform heart bypass surgery. To perform MICS, a very small three-inch cut is made between the ribs instead of the long cut through the breast bone that is needed with traditional open heart surgery. This means less pain and blood loss, fewer risks for problems, shorter hospital stays and quicker healing time.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gundluth/49124/
It's no surprise that about 1 in 8 women in the United States will develop invasive breast cancer over the course of her lifetime. In fact, for women in the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer. In honor of Breast Cancer Awareness Month in October, our national healthcare expert is here to discuss educating and empowering women to take charge of their own breast health.
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today celebrates 10 years of the availability and success of its NovaSure endometrial ablation system. Since 2001, more than one and a half million women have been treated with the NovaSure system to reduce or eliminate their heavy periods, without the need to undergo hysterectomy. The NovaSure procedure is a one-time, five-minute procedure that can be performed in the doctor’s office with very minimal recovery time.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hologic/50096/